Healthy Hearts: Pharmacists Leading the Charge in Cardiovascular Health

A randomized controlled trial showing that community pharmacist interventions significantly reduce systolic blood pressure, double medication adherence, and achieve high patient satisfaction.

Updated:

8 September 2026

Abstract:

Background: Cardio vascular diseases (CVDs) remains the leading cause of morbidity and mortality worldwide posing significant challenge to healthcare systems. While traditional prevention strategies often overlook the role of community pharmacist, their accessibility and frequent patient interactions position them uniquely to contribute to CVD management.

Objective: This study aim to evaluate the impact of pharmacist-led interventions on cardiovascular outcomes, specifically focusing on health promotion, patient screening, and medication adherence support.

Methods: The study utilized a randomized controlled design, comparing an intervention group (receiving pharmacist-led care, including education and lifestyle advice) with a control group (receiving standard care).

Key outcomes measured included systolic blood pressure (BP) and medication adherence rates over a 3-month follow-up period.

Results: The intervention group showed a significant reduction in systolic blood pressure, reaching an average of 125 mmHg compared to 145 mmHg in the control group. Furthermore, medication adherence significantly improve to 85% in the intervention group, compared to 50% in the control group, while patient satisfaction reached a high of 98%.

Conclusion: Pharmacist-led interventions can significantly improve cardiovascular health outcomes in community settings. These findings support the integration of pharmacist into primary healthcare teams to optimize CVD prevention and management

Keywords: Pharmacist-led interventions, Cardiovascular health, Medication adherence

Introduction

Cardiovascular diseases (CVDs) remains the leading cause of morbidity and mortality worldwide, posing significant challenge to healthcare systems and economies. Despite advancements in diagnostics and treatment, there is persistent gaps in both primary and secondary prevention. While most prevention strategies traditionally focused on physicians, the vital role of pharmacists in promoting cardiovascular health is often overlook.

Community pharmacists, due to their accessibility and frequent patient interactions, is in a unique position to contribute significantly to cardiovascular disease management. Recent literature has increasingly recognize the effectiveness of pharmacist-led interventions in improving outcomes, including better blood pressure control and medication adherence. Studies conducted in countries such as Canada and the U.S. have shown that integrating pharmacists into healthcare teams can reduce the burden on physicians.

This study aims to evaluate the role of pharmacists in enhancing cardiovascular health through health promotion and patient screening. It seeks to assess the impact of pharmacist-led interventions on cardiovascular outcomes and propose strategies to optimize this role within modern healthcare systems.

Methods

The study utilized a randomized controlled design to evaluate the impact of pharmacist-led interventions on cardiovascular outcomes. A total of 120 participants were recruited based on specific cardiovascular risk criteria and were randomly assigned into two equal groups (n=60 per group): the intervention group and the control group.

Initially, patient screening was conducted to identify cardiovascular disease (CVD) risk factors, including hypertension, high cholesterol, and smoking status. All eligible participants provided informed consent before undergoing random assignment to ensure the integrity of the trial and eliminate selection bias.

Intervention Group (n=60): This group received comprehensive pharmacist-led care, which included personalized patient education, medication therapy management (MTM) reviews, and lifestyle modification advice. Participants were monitored through a 3-month follow-up period to ensure consistency of care.
Control Group (n=60): This group received standard medical care and routine monitoring without additional clinical pharmacist interventions.

Data collection and analysis were performed at the end of the 3-month study period to compare clinical and patient-centered outcomes between the two groups. The primary outcomes measured included changes in average systolic blood pressure (BP) and medication adherence rates, while patient satisfaction was assessed as a secondary outcome to evaluate the humanistic impact of the intervention.

Results

The results of the study show a significant differences between the two groups. In the intervention group, the average Systolic BP was 125 mmHg, while the control group reaching 145 mmHg. This indicate that pharmacist-led care is more better for patient health. Also, for medication adherence, the intervention group has 85% adherence rate, but the control group was only 50%. Finaly, the patient satisfaction in pharmacist group was 98% which is very high and prove that pharmacists improve the patient experience.

**Figure 1: Flowchart of the study methodology and participants assignment. The process show how we choose and follow the patients.**

The flowchart above illustrates the progression of participants through the study phases. Initially, patients were screened based on CVD risk factors. After identification, they were randomly assigned into two groups to ensure no bias in the results. This process is essential to maintain the integrity of the clinical trial and show how pharmacists can manage patient follow-up over a 3-month period.

Measure	Intervention group	Control group
Systolic BP (avg)	125mmHg	145mmHg
Medication Adherence	85%	50%
Patient Satisfaction	98%	85%
Table 1: Comparison of Clinical and Patient Outcomes.

Looking at Table 1, we can see a clear gap between the intervention and control groups. The Systolic BP in the intervention group decreased significantly, which is a positive indicator. Morever, the medication adherence rate (85%) shows that when pharmacist educates the patient, the patient becomes more committed to their treatment plan. This is a very important finding for healthcare providers.

**Figure 2: Visual comparison of Patient outcomes.**

This bar chart provides a visual evidence of the study success. It is clear that the blue bars (Intervention) is outperforming the orange bars (Control) in all aspects. Specially in patient satisfaction which reaching 98%, which is a very great result for the pharmacy team. This high level of satisfaction reflecting the trust that patients have in pharmacists during the 3 months. Therefor, the chart show why pharmacists are leaders in cardiovascular health and why patients like this care.

Discussion

The results of this study show that clinical pharmacists have a big impact on heart health. When we compare the intervention group with the control group, it is very clear that pharmacist-led care is more better. The reduction in Systolic BP from 145 mmHg to 125 mmHg is a huge success. This happened because pharmacists provide education to the patients about their medications and lifestyle.

Also, the high adherence rate (85%) in the intervention group prove that patients become more committed when they have someone to talk to in the pharmacy. In the control group, adherence was only 50% because maybe they don't have enough information. Our results are similar to other studies that say pharmacists can improve hypertension.

Finally, the 98% satisfaction rate is very amazing. This show that patients in Jordan like to receive care from pharmacists. They feel more comfortable and they trust the pharmacist advice. Therefor, adding pharmacists to the cardiovascular team is a very important step for the healthcare system to save lives and reduce costs.

Conclusion

In conclusion, our research "Healthy Hearts" prove that pharmacists are leaders in cardiovascular health. The study show that pharmacist intervention can lower blood pressure and increase medication adherence. Also, patients are very happy with this service as we see in the 98% satisfaction. We recommend that all clinics should have a clinical pharmacist to help patients with heart disease. This will make the healthcare more better for everyone in the future.

References

American Heart Association. (2024). Cardiovascular health and pharmacist intervention strategies. Retrieved from https://www.heart.org

Jordan Ministry of Health. (2025). National guidelines for hypertension management in community pharmacies. Amman, Jordan: MOH Press.

Smith, J., & Al-Amiri, M. (2023). The impact of pharmacist-led counseling on medication adherence in chronic disease patients. Journal of Clinical Pharmacy and Therapeutics, 48(2), 145-152.

World Health Organization. (2023). Improving medication adherence: The role of healthcare providers. Geneva: WHO Press.

Kyrios Research Group. (2026). Patient satisfaction and humanistic outcomes in pharmacy-led clinics. International Journal of Health Sciences, 12(1), 33-40.